In separate in vitro tests against two strains of the H5N1 avian bird flu subtype, both instances of the virus were successfully neutralized by the American Biotech Labs' ABL SilverSol Technology products; the most recent findings are consistent with prior test using company products against the H3N2 and H1N1 flu subtypes.

SALT LAKE CITY, Oct. 9 /PRNewswire-FirstCall/ - American Biotech Labs (ABL; www.AmericanBiotechLabs.com), creator of a line of powerful products that utilize patented ABL SilverSol Technology(TM) to combat many of the world's most harmful pathogens, today announced successful preliminary results on tests performed using the company's products against three strains of the avian bird flu virus.

Preliminary in vitro tests performed by two separate independent laboratories, using the company's ABL SilverSol Technology(TM) at 10 parts per million against two strains of the H5-N1 and H3-N2 subtype of the Avian Bird Flu virus, indicated that the ABL products could neutralize the virus.

"While we understand that these are preliminary studies, we are extremely encouraged by the results of this initial testing," said Keith Moeller, a managing director at American Biotech Labs. "Our intent with these studies is to test the ability of the product to disarm or kill the Avian flu virus in a laboratory setting. It is a necessary and valuable next step in our continued efforts to gain an understanding of what this technology can do."

The preliminary results of the tests using ABL products against the H5N1 avian bird flu virus are consistent with a variety of previous tests conducted using company products against the H3N2 and H1N1 flu subtypes. In all cases, ABL SilverSol Technology(TM) was able to successfully neutralize the virus.

ABL is engaged in continuing testing and study programs with a variety of groups and labs in the United States and other nations examining the potential applications of ABL SilverSol Technology […].

Tuesday, October 18, 2005 - FreeMarketNews.com

In a groundbreaking study, the Journal of Nanotechnology has published a study that found silver nanoparticles kills HIV-1 and is likely to kill virtually any other virus. The study, which was conducted by the University of Texas and Mexico University, is the first medical study to ever explore the benefits of silver nanoparticles, according to Physorg.

During the study, researchers used three different methods of limiting the size of the silver nanoparticles by using capping agents. The capping agents were foamy carbon, poly (PVP), and bovine serum albumin (BSA). The particles ranged in size from 1 to 10 nanometers depending on the method of capping. After incubating the HIV-1 virus at 37 C, the silver particles killed 100% of the virus within 3 hours for all three methods. The scientists believe that the silver particles bonded through glycoprotein knobs on the virus with spacing of about 22 nanometers in length.

While further research is needed, researchers are optimistic that nanological silver may be the silver bullet to kill viruses. The researchers in the study said that they had already begin experiments using silver nanoparticles to kill what is known as the super bug (Methicillin resistant staphylococcus aureus). Already used as a topical antibiotic in the medical industry, silver may now come under consideration as an alternative to drugs when it comes to fighting previously untreatable viruses such as the Tamiflu resistant avian flu.

staff reports - Free-Market News Network
http://www.physorg.com/news7264.html

ALPINE, UT, Jan. 31, 2006 /PRNewswire-FirstCall/

American Biotech Labs (ABL), a private company (Clifton Mining Company owns over 24% of ABL) has just received the largest single order in the company's history, doubling its previous record. The private label order from a European company was for 150,000 bottles of ABL product. The largest previous single order was for 75,000 bottles. The company that just purchased the 150,000 bottles from ABL has been a client of ABL for five years and started with a single order of only 2,500 bottles at a time.

Said Keith Moeller, a managing director for the company, "Management sees this steady growth as the ultimate verification of the product's effectiveness. Double digit growth is occurring in almost every market sector. This growth is occurring not just through the acquisition of new accounts, but through existing accounts as well. Last year saw sales growth near 50%. The order we have just received lays a foundation for another excellent year. In addition, the company is planning to release two new products this summer."

ALPINE, UT, June 17 /CNW/ - Clifton Mining Company ("Clifton")(OTC:CFTN)

American Biotech Labs ("ABL"), a private company in which Clifton owns a 28% interest, has signed an agreement with BRAM Lab Technologia, SA ("BRAM"), to produce ASAP Solution(R) in Brazil. According to the terms of this agreement, ABL will receive a net sales royalty of 12 to 22%, with a minimum of $5 per liter, on all BRAM sales of the solution. The minimum royalty payable to ABL will be $57,000 per month and will be paid by the 15th day of the following month once commercial production is achieved.

Commercial production is expected, in the next three months, to reach a level of 3,000 gallons per month. A spokesman for BRAM has informed ABL that they are in direct communication with all federal Brazilian laboratories with the purpose of expediting acceptance as a human drug, including prophylaxis.

Clifton trades on the U.S. OTC: (CFTN).